Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-115 in Male Androgenetic Alopecia
NCT06118866Phase 2Completed
- Sponsor
- HopeMed
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HMI-115 in androgenetic alopecia (AGA) (4 arms), sponsored by HopeMed. Primary endpoint: Rate of Target Area Hair Count at 24 weeks. Started Sep 2023; status: completed.
02
Drugs
HMI-115
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06118866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118866.